A Prospective, Multicentric, Feasibility Investigation to Assess the Effect of the Tinnitus Implant on Tinnitus Loudness in Adults With Moderate to Severe Chronic Tinnitus Accompanied by Normal Hearing to Moderately Severe Hearing Loss.

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study will test an experimental Tinnitus Implant System that consists of a cochlear implant, sound processor and programming software. The Tinnitus implant is surgically placed under the skin just behind the ear in the mastoid bone. It has an electrode that extends from the implant into the promontory bone of the cochlea which emits electrical signals that stimulate the auditory nerve. The sound processor is worn behind the ear and powers the implant via the coil. The study will be conducted in adults with moderate to severe chronic tinnitus who have normal hearing to moderately severe hearing loss in the inner ear. The study participants will undergo a series of tests that include evaluations of tinnitus loudness and annoyance, and self-reported questionnaires on their tinnitus and general health.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• 18 years or older.

• Normal hearing to moderately severe sensorineural hearing loss defined as a pure tone average (PTA) at 500, 1000, 2000 and 4000 Hz less than 65 dB HL in both ears (separately) and best-aided phoneme recognition score more than or equal to 80% in both ears (separately).

• Unilateral or asymmetric subjective (no pulsatile) tinnitus. In case of asymmetric tinnitus, the worst ear must be implanted.

• Tinnitus duration of at least 6 months.

• Severe tinnitus loudness determined by a. VAS-L score in the severe range i.e. 50-100/100 b. TFI score in the severe range i.e. 52-90/100

• Tinnitus that is intractable and has not been ameliorated satisfactorily by standard of care such as CBT or hearing aid, when such interventions are potentially clinically indicated.

• Clinically significant reduction in VAS-L score (≥ 15/100 points) in response to trans-tympanic promontory stimulation

• Willing and able to provide written informed consent.

• Medically able to use the device and to undergo general anaesthesia for implantation taking into account their medical condition, contraindications and surgical risks.

• Dutch language proficiency

Locations
Other Locations
Belgium
Antwerp University Hospital (UZA)
RECRUITING
Edegem
Netherlands
University Medical Center Utrecht
RECRUITING
Utrecht
Contact Information
Primary
Remo Arts
rarts@cochlear.com
+31615326086
Backup
Kelly Assouly
kassouly@cochlear.com
Time Frame
Start Date: 2025-05
Estimated Completion Date: 2026-04
Participants
Target number of participants: 16
Treatments
Experimental: Tinnitus Implant System
Tinnitus Implant
Related Therapeutic Areas
Sponsors
Leads: Cochlear

This content was sourced from clinicaltrials.gov